Brentuximab vedotin is indicated for:
Population group: only adults (18 years old or older)
Brentuximab vedotin is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Brentuximab is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Brentuximab vedotin is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Brentuximab vedotin is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):
1. following ASCT, or
2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Brentuximab vedotin is indicated for the treatment of adult patients with relapsed or refractory sALCL.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Brentuximab vedotin is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.